Malnutrition in Chronic Gastrointestinal Diseases Cross-sectional Study

  • STATUS
    Recruiting
  • participants needed
    320
  • sponsor
    University Medicine Greifswald
Updated on 19 February 2024
ct scan
computed tomography
MRI
endoscopic ultrasound
cirrhosis
gastroscopy
gastrointestinal disorders
malnutrition
liver cirrhosis
hepatocellular carcinoma
body measurements
gastrointestinal disease
short bowel
pancreatitis
gastritis
muscle wasting
chronic diseases
short bowel syndrome
bowel resection
cysts
pancreatic resection
pancreaticojejunostomy
mrcp
magnetic resonance cholangiopancreatography

Summary

Malnutrition and muscle wasting are common consequences of life-threatening, chronic diseases of the gastrointestinal tract. Such diseases include liver cirrhosis, chronic pancreatitis and short bowel syndrome. Malnutrition and muscle wasting increase the risk of complications, reduce the life expectancy and impair the quality of life. The development of malnutrition and muscle wasting is different, as is the diagnosis and nutritional treatment. There are also different mechanisms of origin for the underlying diseases. The aim of the study is to compare data related to nutrition and physical condition of patients with liver cirrhosis, chronic pancreatitis and short bowel syndrome. Malnutrition and muscle wasting within the specific diseases will be characterized and possible correlations will be identified.

For this, malnourished and non-malnourished patients of the different diseases are compared with controls patients with non-specific complaints of the gastrointestinal tract as well as with healthy study participants.

Data on food intake, physical activity, body composition and body measurements as well as muscle strength and muscle function are recorded. Blood values as well as transport and barrier properties of the intestine will also be examined.

Description

Malnutrition and sarcopenia are consequences of life-threatening gastroenterological diseases such as liver cirrhosis, chronic pancreatitis and short bowel syndrome and are associated with a poorer clinical outcome and a reduced quality of life. The diagnostic criteria of both conditions differ, as do the consequences for adequate nutritional therapy. Nevertheless, malnutrition and sarcopenia are often discussed in confusion in the literature. In addition, the underlying mechanisms of malnutrition and sarcopenia can differ in the various diseases. The aim of the study is to compare nutrition-associated parameters from patients with liver cirrhosis, chronic pancreatitis and short bowel syndrome, to characterize the disease-specific phenotype of malnutrition and sarcopenia of the examined diseases and to obtain information on mechanistic relationships. The pathophysiological understanding of the clinical settings as well as the development of malnutrition and sarcopenia is important for choosing specific nutritional therapies. For this, malnourished and non-malnourished patients of each examined disease are compared with controls from patients with non-specific, abdominal symptoms and healthy control subjects. Data on food intake, physical activity, body composition and anthropometry as well as muscle strength and muscle function are recorded. Clinical and chemical blood parameters, the plasma metabolome as well as transport and barrier proteins of the intestine are also examined.

Details
Condition Cirrhosis, LIVER DISEASE, LIVER DISEASE, Short Bowel Syndrome, Chronic pancreatitis
Age 18-100 years
Treatment No intervention - cross-sectional observational only
Clinical Study IdentifierNCT04474743
SponsorUniversity Medicine Greifswald
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Liver Cirrhosis
based on clinical and imaging criteria (sonography or computed tomography (CT) or magnetic resonance imaging (MRI)) without evidence of hepatocellular carcinoma
Child-Pugh Stadium A-C
Chronic Pancreatitis
based on imaging criteria (endoscopic ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography (MRCP))
large and small duct disease
with or without exocrine insufficiency
with or without endocrine insufficiency
patients after left pancreatic resection or pancreaticojejunostomy or duodenal pancreatic head resection
Short Bowel Syndrome (SBS)
based on clinical anamnestic criteria and state after bowel resection followed by primary or secondary oral autonomy (intestinal failure)
Control Patients
patients without known underlying gastroenterological disease with an indication for esophago-gastro-duodenoscopy for symptom clarification
negative Nutritional Risk Screening (NRS-2002 < 3)
gastroscopy without clinically relevant result (mild gastritis aspect, small axial hernia, typical glandular cysts, typical brunneromas can be included)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria

General Exclusion Criteria
parenteral nutrition in the previous 6 months
pacemaker or implanted defibrillator
pregnancy or lactation
lack of ability to answer the questionnaires
taking certain medications during the previous 4 weeks (protein pump inhibitors and H2 antagonists, except medication on demand or 4 weeks continuously, antibiotics, narcotics, non-opioid analgesics except medication on demand ( 1 day/week), anticholinergics, antidepressants, motility drugs (metoclopramide, motilium, bromocriptine, prucalopride), thyroid drugs except stable thyroid hormone substitution with euthyroid metabolism, steroids, immunomodulators, anti-inflammatory biologics)
Subsequent Exclusion of Control Patients
if, contrary to expectations, malnutrition is diagnosed in spite of an inconspicuous NRS-2002 within the framework of the study
as well as in the case of relevant, conspicuous esophago-gastro-duodenoscopy findings
Specific Exclusion Criteria
Liver Cirrhosis
steatohepatitis according to clinical or laboratory parameters
acute alcoholic hepatitis according to clinical and imaging parameters (sonography, CT, MRI)
existing transjugular intrahepatic portosystemic shunt (TIPS)
known hepatocellular carcinoma (HCC)
state after liver transplantation
Chronic Pancreatitis
acute pancreatitis
extrapancreatic infection
coexisting liver cirrhosis based on clinical and imaging parameters
state after surgery with alteration of food flow (partial or total pancreaticoduodenectomy)
known pancreatic carcinoma or state after therapy of pancreatic carcinoma (surgery or chemotherapy or radiation)
Short Bowel Syndrome (SBS)
acute phase of intestinal insufficiency (less than 28 days after resection)
intravenous substitution of macronutrients (water, electrolytes, glucose, amino acids or lipids (intestinal insufficiency)
intramuscular substitution of micronutrients is allowed (e.g. vitamin B12)
uncontrolled underlying disease leading to SBS (e.g. active Crohn's disease)
Control Patients
major underlying and concomitant diseases
food allergies
Healthy controls
tumor diseases in the past 5 years
medically diagnosed, serious chronic diseases or changes in the gastrointestinal tract that may affect the absorption of nutrients (e.g. celiac disease, chronic inflammatory bowel disease or irritable bowel syndrome diagnosed according to Rome IV criteria, relevant bowel resections including short bowel syndrome)
rheumatic diseases requiring permanent drug therapy (rheumatoid arthritis, fibromyalgia)
chronic use of anti-inflammatory or pain-relieving drugs or use of anti-inflammatory or pain-relieving drugs for more than 3 days in the last 3 weeks
average daily alcohol consumption > 20 g in women and > 30 g in men
diagnosed severe liver disease requiring medical attention and drug therapy (liver cirrhosis, non-alcoholic steatohepatitis (NASH) / alcoholic steatohepatitis (ASH), hepatitides)
acute or chronic pancreatitis
acute and chronic renal failure
myocardial infarction or cerebral insult within 6 months prior to examination
coronary artery disease/pAVK (peripheral artery disease (PAD))
heart failure with stages 3 and 4 according to NYHA (New York Heart Association) classification
severe chronic pulmonary disease (COPD)
history of significant neurological or psychiatric diseases (including epilepsy, bipolar disorders, dementia and neuromuscular diseases)
presence of pareses including mono- and diparesis
rare congenital metabolic diseases (cystic fibrosis, phenylketonuria)
expected altered body composition (extreme sports activity < 2h/day), edema, amputation of the extremities (arm and/or leg)
highly atypical or restrictive dietary choices/concepts followed voluntarily (macrobiotics, paleo-diet, Atkins diet, Mayo diet, instinctive diets) or due to food intolerances/allergies
simultaneous participation in other studies associated with drug use and potentially having a significant impact on body composition or dietary behaviour
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 â€˘ 

Private

Reply by • • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.